View the CAT printer-friendly / share this CAT
Title Enamel Matrix Proteins Improve Clinical Outcomes in the Treatment of Intrabony Defects
Clinical Question In patients with intrabony defects, does the adjunctive use of Emdogain result in greater long-term reduction in clinical attachment levels (CAL), pocket depths (PD), and other clinical improvements as compared to bone grafting alone?
Clinical Bottom Line The addition of enamel matrix proteins when bone grafting intrabony defects with demineralized freeze-dried bone allografts resulted in better clinical outcomes at 12 months.
Best Evidence (you may view more info by clicking on the PubMed ID link)
PubMed ID Author / Year Patient Group Study type
(level of evidence)
#1) 20054593Aspriello/201156 patientsRandomized clinical trial
Key resultsThe test group was enamel matrix derivative (EMD) + demineralized freeze-dried bone allograft (DFDBA), and the control group was DFDBA alone for the treatment of periodontal intrabony defects. The test groups showed statistically significant better results than the control group in PD reduction (5.0 mm vs. 4.0 mm; P < 0.05), CAL gain (4.0 mm vs. 3.25 mm), and hard tissue fill (4.0 mm vs. 3.5 mm; P < 0.05) at 12 months post-surgery.
Evidence Search Enamel matrix derivative AND intrabony bone graft
Comments on
The Evidence
Validity: Several factors contributed to the validity of this experiment, including a double-blinded design wherein the patient and the investigator who took the clinical measurements were both blinded as to the treatment, random assignment of patients to the test or control group, and an accurate comparison of bone fill between baseline and 12 months by using a stent/template for the radiographs. The study length of 12 months is a reasonable follow-up time in that at that point the tissues should be completely healed and stable, and lastly 100% of the patients completed the study. Perspective: This randomized clinical trial was well conducted and designed. However, even though the addition of Emdogain resulted in statistically better results in PD reduction, CAL gain, and hard tissue fill, the differences might not be clinically significant; for example, a difference of 0.5 mm more hard tissue fill might not be enough to merit using Emdogain. Furthermore, I would find the results to be more convincing if more studies were done by other researchers with similar results.
Applicability Emdogain is an enamel matrix extract designed to help regenerate the loss of bone and soft tissues due to periodontitis. It helps promote periodontal regeneration, including the formation of new bone, cementum, and attachment fibers. The use of Emdogain is indicated in the treatment of moderate or severe periodontitis, the treatment of gingival recession defects, etc. Emdogain is a cost-effective treatment available in a small volume (0.15 ml). An additional patient benefit of Emdogain is less patient discomfort post-surgery.
Specialty/Discipline (General Dentistry) (Oral Surgery) (Periodontics)
Keywords Enamel matrix derivatives, demineralized freeze-dried bone allograft
ID# 3209
Date of submission: 04/26/2017spacer
E-mail reald@livemail.uthscsa.edu
Author Diana Real
Co-author(s) e-mail
Faculty mentor/Co-author Suman Challa, BDS, MS
Faculty mentor/Co-author e-mail challas@uthscsa.edu
Basic Science Rationale
(Mechanisms that may account for and/or explain the clinical question, i.e. is the answer to the clinical question consistent with basic biological, physical and/or behavioral science principles, laws and research?)
post a rationale
None available
Comments and Evidence-Based Updates on the CAT
post a comment
None available

Return to Found CATs list